Back

Impact of glycated hemoglobin A1c on cardiovascular risk in diabetes patients with and without coronary artery disease

27 August 2023 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart (3) Diabetes and the Heart ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Malene Kaerslund Hansen

Regionshospitalet Randers, Aarhus (Denmark)

6 More presentations in this session

Presentation thumbnail
Risk of incident renal cell carcinoma in patients with type 2 diabetes on sodium-glucose co-transporter-2 inhibitor users: a population-based cohort study
Professor G. Jong (Taichung, TW)
Abstract Slides Video
Presentation thumbnail
Fifteen-year follow-up and impact of age and sex on cardiovascular outcomes in diabetes and non-diabetes patients without CAD
Doctor P. Thrane (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
The impact of glycated hemoglobin A1c on cardiovascular risk in patients with and without coronary artery disease
Doctor K. Olesen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Elevated remnant cholesterol in atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study
Doctor B. Nilsson Wadstrom (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on vascular function and liver steatosis in diabetes
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and the heart (3)

The Event

Event poster

ESC Congress 2023

27 August 2023 13:15 CET
You may be interested in
thumbnail
Congress Presentation
The impact of glycated hemoglobin A1c on cardiovascular risk in patients with and without coronary artery disease
thumbnail
Congress Presentation
Change in hbA1c following treatment with and the short-term risk of major adverse cardiovascular outcomes
thumbnail
Congress Presentation
Association of HbA1C with mortality and cardiovascular outcome in patients with type 2 diabetes using drugs with different hypoglycemic risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources